Evidence map›Paper›PMID 27122980›Full record

ArticleCurrent oncology (Toronto, Ont.)2016

Hematogones: a sensitive prognostic factor for Chinese adult patients with acute myeloid leukemia.

L Li, R Fu, T Zhang, X Xie, J Liu, J Tao, J Song, H Liu, W Zhang, W Lu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Impact of CD34European journal of haematology · 2026
    Article
  2. Analytical Appraisal of Hematogones in B-ALL MRD Assessment Using Multidimensional Dot-Plots by Multiparametric Flow Cytometry: A Critical Review and Update.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

L LiDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin, P.R.C.;
R FuDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin, P.R.C.;
T ZhangDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin, P.R.C.;
X XieDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin, P.R.C.;
J LiuDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin, P.R.C.;
J TaoDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin, P.R.C.;
J SongDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin, P.R.C.;
H LiuDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin, P.R.C.;
W ZhangDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin, P.R.C.;
W LuDepartment of Health Statistics, School of Public Health, Tianjin Medical University, Tianjin, P.R.C.
Z ShaoDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin, P.R.C.;
Tianjin Medical University · CNTianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHematogones (hgs) are normal B-lymphocyte precursors that increase in some hematologic diseases. Many studies indicate that hgs might be a favourable prognostic factor. We thus considered it important to determine whether hgs are also a prognostic factor for Chinese adult patients with acute myeloid leukemia (aml) and whether the hg-positive and hg-negative groups show any serologic or phenotypic differences.

methodsChinese adult aml patients (n = 177) who were all initially hg-negative underwent standard chemotherapy and were thereafter divided into hg-positive and hg-negative groups according to hg levels in bone marrow during their first remission.

resultsThe follow-up study confirmed that survival duration (both leukemia-free and overall) was significantly greater in the hg-positive group than in the hg-negative group and was accompanied by a lower relapse rate. A retrospective study of patient characteristics at the time of first diagnosis revealed some differences between the hg-positive and the hg-negative groups, including elevations in white blood cells, lactate dehydrogenase, and β2-microglobulin in the hg-negative group. Retrospective phenotypic analysis revealed a significantly lower proportion of abnormal chromosome karyotype and CD34 expression in hg-positive patients. Finally, we evaluated whether additional intensive chemotherapy after standard chemotherapy could further increase hgs.

conclusionsThe present work verified the validity of hgs as a prognostic factor for Chinese adult patients with aml. Compared with hg-negative patients, hg-positive patients not only experienced longer survival and a lower relapse rate, but they also had some serologic and phenotypic characteristics that are all considered indicators of better outcome. Additional intensive chemotherapy could further increase the level of hgs, which might imply better clinical results.

Indexed as

Acute myeloid leukemiahematogonesintensive chemotherapyprognosisstandards

Identifiers

PMID27122980
PMCPMC4835019
OpenAlexW2339393782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.